SEOUL, April 1 (Korea Bizwire) — South Korean drugmaker Medytox Inc. said Friday it has filed a complaint with a U.S. trade panel against domestic rival botox maker Hugel Inc. over a botulinum toxin strain. The complaint lodged with the U.S. International Trade Commission (ITC) targets top South Korean botox maker Hugel, its U.S. and [...]
SEOUL, Feb. 22 (Korea Bizwire) — South Korea’s leading botox maker Hugel Inc. said Tuesday its botulinum toxin product, Letybo, has won approval from Austrian drug authorities. The Austrian Federal Office for Safety in Health Care granted the use of Letybo for the treatment of frown lines in adult patients. It marks the first time [...]
SEOUL, Feb. 11 (Korea Bizwire) — South Korea’s leading botox maker Hugel Inc. said Friday that it will make inroads into the United States, the world’s largest botulinum toxin market, this year. Earlier, the company sought a marketing authorization of its botulinum toxin product, Letybo, with the U.S. Food and Drug Administration (FDA) for the [...]
SEOUL, Aug. 25 (Korea Bizwire) — South Korea’s leading botox maker Hugel Inc. said Wednesday a multinational consortium led by local conglomerate GS Holdings Corp. bought a majority stake in the company from American private equity firm Bain Capital for 1.7 trillion won (US$1.5 billion). Bain Capital-owned Leguh Issuer Designated Activity Co. struck a deal [...]
SEOUL, Oct. 14 (Korea Bizwire) – The market for botulinum toxin (BTX), commonly marketed as botox, is rapidly expanding in Korea. But fierce competition between Korean botox distributors has recently intensified, with businesses questioning the safety of each other’s products. There are currently seven BTX distributors globally, three of which are Korean – Medytox, Hugel, [...]